Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal Esketamine with Mometasone or Oxymetazoline
NCT02154334Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esketamine in major depressive disorder (MDD) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Concentration and 3 more. Started Jun 2014; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02154334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154334.